Ellevest, Inc. Exelixis, Inc. Transaction History

Ellevest, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	SELL	$14.96 - $17.39 $897 - $1,043	-60 Reduced 23.53%	195 $3,000
Q3 2022 Nov 02, 2022	BUY	$15.68 - $22.27 $3,512 - $4,988	224 Added 722.58%	255 $4,000
Q2 2022 Jul 18, 2022	BUY	$17.44 - $23.16 $313 - $416	18 Added 138.46%	31 $1,000
Q1 2022 Apr 19, 2022	BUY	$17.03 - $22.67 $221 - $294	13 New	13 $0
Q3 2021 Oct 19, 2021	SELL	$16.3 - $21.14 $2,298 - $2,980	-141 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$17.95 - $25.56 $412 - $587	23 Added 19.49%	141 $3,000
Q1 2021 May 03, 2021	BUY	$20.53 - $25.22 $636 - $781	31 Added 35.63%	118 $3,000
Q4 2020 Feb 04, 2021	SELL	$18.39 - $24.8 $7,374 - $9,944	-401 Reduced 82.17%	87 $2,000
Q3 2020 Oct 26, 2020	BUY	$20.67 - $26.94 $1,984 - $2,586	96 Added 24.49%	488 $12,000
Q2 2020 Jul 06, 2020	SELL	$16.46 - $27.42 $2,732 - $4,551	-166 Reduced 29.75%	392 $9,000
Q1 2020 Apr 13, 2020	BUY	$14.46 - $21.8 $3,051 - $4,599	211 Added 60.81%	558 $10,000
Q4 2019 Feb 05, 2020	BUY	$15.15 - $18.89 $5,257 - $6,554	347 New	347 $6,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.